Medprin Regenerative Medical Technologies Co., Ltd. (SHE:301033)
47.53
-0.11 (-0.23%)
At close: Oct 19, 2026
SHE:301033 Revenue
Medprin Regenerative Medical Technologies had revenue of 111.44M CNY in the quarter ending June 30, 2026, with 32.55% growth. This brings the company's total for the last twelve months to 400.85M, up 27.59% year-over-year. In the year 2025, Medprin Regenerative Medical Technologies had annual revenue of 368.83M with 32.46% growth. That makes Medprin Regenerative Medical Technologies the 26,576th largest company in the world by revenue and 4,672nd in China.
Revenue (ttm)
400.85M
Revenue Growth
+27.59%
P/S Ratio
7.92
Revenue / Employee
896.77K
Employees
447
Market Cap
3.18B
Revenue by Segment
Fiscal year ended Dec 31, 2025 See the full SHE:301033 breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 368.83M | 90.39M | 32.46% |
| Dec 31, 2024 | 278.44M | 47.57M | 20.61% |
| Dec 31, 2023 | 230.87M | 35.62M | 18.24% |
| Jan 1, 2023 | 195.25M | 41.47M | 26.96% |
| Jan 1, 2022 | 153.79M | 30.27M | 24.51% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Shanghai Kehua Bio-Engineering Co.,Ltd | 1.69B |
| Guangdong Biolight Meditech | 1.10B |
| Shanghai Aohua Photoelectricity Endoscope | 793.05M |
| Ningbo David Medical Device | 584.68M |
| Chison Medical Technologies | 441.10M |
| Tellgen | 392.11M |
| Shanghai General Healthy Information and Technology | 371.61M |
| Beijing Leadman Biochemistry | 317.79M |